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Background: Fecal calprotectin (FC) correlates with endoscopic recurrence of Crohn's disease (CD) in adults but
has not been studied among children postoperatively. We aimed to analyze whether FC relates with postopera-
tive CD recurrence in children.
Methods: Altogether 51 postoperative endoscopies and FC measurements from 22 patients having undergone
surgery for CD at age ≤18 years were included.
Results: Ileocecal resection (n = 15), small bowel resection (n = 6), or left hemicolectomy (n = 1) was per-
formed atmedian age of 15.1 (interquartile range 14.4–17.6) years. Following surgery, FC decreased significantly
(659 vs. 103 μg/g, p = 0.001). During median follow-up of 5.7 (4.2–7.7) years, either endoscopic or histological
recurrence occurred in 17 patients (77%). FC N139 μg/g at time of endoscopy or FC increase of 79 μg/g compared
to first postoperative value was suggestive of endoscopic recurrence (Rutgeerts score i2-i4), while FC N101 μg/g
or increase of 21 μg/g indicated histological recurrence. Best accuracy for prediction of recurrence was obtained
by combining FC at endoscopy and the postoperative increase of FC. The corresponding AUROC values were 0.74
(95% 0.58–0.89) for endoscopic recurrence whereas 0.81 (95% CI 0.67–0.95) for histological recurrence.
Conclusion: FC is a useful surrogate marker of postoperative recurrence also in pediatric CD patients.
© 2016 Elsevier Inc. All rights reserved.Crohn's disease (CD) is a chronic relapsing inflammatory disorder of
the alimentary tract with a continuously increasing incidence in the pe-
diatric population [1–5]. Compared to adults, childhood-onset CD typi-
cally shows a more active disease pattern and greater need for
immunosuppressant therapy [4]. Ileum is affected in 70% of children
and is prone to stricture and fistula formation, which occur in about
25% of pediatric CD patients [3,4,6]. Resection of the affected bowel seg-
ment either because of such complications or for unresponsive luminal
disease is performed in 30–50% of pediatric CD patients by young adult-
hood [4,7] and as many as 70% of operated patients require further sur-
gery during their lifetime [8,9].
Recurrent mucosal inflammation is observed in endoscopy in
70–90% of adult CD patients within a year of surgery although onlyctin; MRE, magnetic resonance
r receiving operating character-
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nen).one third presentwith symptomatic relapse of the disease [1,8–10]. His-
tological activity may develop at the site of the anastomosis as soon as
after a week of bowel resection [11]. Even though longer postoperative
remission periods are reported for children, most studies have moni-
tored clinical recurrence rates instead of endoscopic follow-up
[2,12–15]. As clinical symptoms are frequently absent and serum bio-
chemical markers normal until significant inflammatory changes have
developed, ileocolonoscopywith histological verification should be con-
sidered as the gold standard for assessing disease activity and postoper-
ative recurrence [6,8–10,16].
Calprotectin is a neutrophil-derived protein excreted in stool in
abundance in the presence of mucosal inflammation [17–20]. Fecal
calprotectin (FC) outperforms serum markers in the detection of
bowel wall inflammation and reflects the endoscopic activity of CD reli-
ably in both children and adults [17,18,20–23]. Its concentration has
been shown to increase in the presence of histological pouch inflamma-
tion following proctocolectomy for ulcerative colitis [24]. In addition, FC
levels correlatewith endoscopic disease recurrence rates after bowel re-
section in adult CD patients [8,25], although not all studies have con-
firmed this association [26,27]. In pediatric Crohn patients, FC has not
been evaluated postoperatively and neither has its correlation with his-
tological recurrence been assessed after surgery. We aimed to evaluate
Table 1




Median age at diagnosis (years) 13.6 (11.9–14.2)
Extraintestinal manifestations, n (%)
Arthralgia 9 (41%)
Primary sclerosing cholangitis 2 (9%)
Erythema nodosum 1 (4.5%)
Gallstones 1 (4.5%)
None 12 (55%)
Perianal CD, n (%) 3 (14%)
Medications used preoperatively,a n (%)
AZA 11 (52%)
Anti-TNF-α agents 6 (29%)
MTX 3 (14%)
CD = Crohn's disease, AZA = azathioprine, TNF-α = tumor necrosis factor α,
MTX = methotrexate.
a Reported for 21 patients.
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scopic and histological recurrence in children and adolescents having
undergone bowel resection for CD.
1. Methods
This was a retrospective study including all patients with childhood-
onset CD having undergone bowel resection at age ≤18 years as well as
postoperative endoscopies and FC measurements in a tertiary care
children's hospital during 1994–2015 (n = 22). Patients without
follow-up endoscopy and FC datawere excluded (n= 7). The diagnosis
of CD was based on upper and lower gastrointestinal endoscopies and
evaluation of histopathological biopsies in all cases. Themedical records
including operative, endoscopy, and pathology reports were reviewed.
The type of surgery, number of bowel resections, possible postoperative
complications as well as medications before and after surgery were
recorded.
1.1. Endoscopy data
Altogether 46 ileocolonoscopies, 3 capsule endoscopies, and 2 mag-
netic resonance enterographies (MRE) (total n = 51) from 22 patients
were included. Endoscopieswere performedwhen clinically considered
necessary. Endoscopy findings were classified according to Rutgeerts
score where remission was defined as i0 (no lesions) or i1 (less than
five aphthous lesions) and recurrence as i2 (N5 aphthous lesions or larg-
er lesions confined to anastomosis), i3 (diffuse ileitis), or i4 (diffuse in-
flammation with large ulcers and/or narrowing) [28,29]. Indications for
MRE were follow-up of ileal disease or terminal ileum not reached in
ileocolonoscopy. Both examinations showed a clearly strictured bowel
segment and were graded as i4.
1.2. Biopsy specimens
Biopsies were taken in ileocolonoscopies from the anastomosis, the
ileum, cecum, ascending colon, colon transversum, descending colon,
sigmoid colon, and rectum. The specimens were evaluated by pediatric
pathologists and the histological findings were graded as quiescent CD
(0) if no inflammation or chronic inflammation without active compo-
nent was present, and active CD (1) if signs of acute inflammation,
such as inflammatory infiltration, crypt injury, crypt abscesses, or ulcer-
ations were detected. In total 43 histology reports from 46
ileocolonoscopies were reviewed.
1.3. Fecal calprotectin
FC was measured with quantitative enzyme immunoassay as previ-
ously described and expressed as μg/g [30]. Preoperative (n = 17) and
postoperative FC measurements (n = 19) were recorded. Follow-up
FC samples (n = 51) were included in the study if measured within
6 months of the endoscopy or MRE.
1.4. Statistical analyses
The descriptive results are presented as medians with interquartile
ranges (IQR). Spearman rank correlation was used to examine associa-
tions between variables. Kruskal–Wallis test and Mann–Whitney
U test were used to compare continuous variables, Wilcoxon signed-
rank test to compare repeatedmeasurements within groups, and Fisher
exact test was applied when comparing frequencies between groups.
Receiving operating characteristic (ROC) curves and areas under ROC
curves (AUROC) were used to evaluate the ability of FC to detect the
presence endoscopic or histological recurrence of CD. The optimal cutoff
values were calculated using the maximum sum of specificity and sen-
sitivity. To evaluate the combination of two different parameters for
the prediction of CD recurrence, the predicted probabilities from abinary logistic regression model were used to plot the respective ROC
curve. The analyses were carried out with SPSS version 22 (SPSS Inc.,
Chicago, IL) and the level of significance was set at p b 0.05.
1.5. Ethics




Altogether 22 eligible patients were identified. Half had extraintesti-
nal manifestations of CD, of which mild arthralgia was the most com-
mon. Symptomatic upper gastrointestinal disease was present in one,
however, aphthous ulcers were seen in endoscopy in the esophagus of
two additional patients. Full medication data were available for 21 pa-
tients, of whom 67% (n = 14) had used immunosuppressive medica-
tions preoperatively while 33% (n = 7) had not (Table 1).
2.2. Operative details
First bowel resection was performed median 2.2 (1.0–4.2) years
after the diagnosis of CD. The strictured or severely affected bowel seg-
ment, most commonly the ileocecal area, was removed in laparoscopy
(n = 9, 41%) or in open surgery (n = 13, 59%) (Table 2). Urgent or
emergency surgery for perforation, bleeding, infection, or occlusion
was scheduled in six patients (27%) while others underwent elective
operations. Postoperative complications were uncommon (Table 2).
Corticosteroids, used prior to surgery in 90% (n = 18), were gradually
tapered and discontinued. Postoperativemedicationswere designed in-
dividually according to disease behavior and estimated risk of recur-
rence (Table 2). Postoperative FC, measured median 1.8 (0.75–2.7)
months after surgery, was significantly lowerwhen compared to preop-
erative FC, measured 4.5 (1.5–5.5) months prior surgery (103 vs.
659 μg/g, p = 0.001, Table 2).
2.3. Follow-up endoscopies
Endoscopy or MRE (n= 51) was performed 38 (15–58)months fol-
lowing the latest surgery at the age of 19.2 (17.5–22.9) years. Endoscop-
ic disease recurrence was observed in half of cases while histological
recurrencewas present in two thirds (Table 3). Patients with endoscop-
ic recurrenceweremore likely to be on immunosuppressivemedication
at time of endoscopy compared to those without recurrence (88% vs.
60%, p = 0.025, Table 3). FC at time of endoscopy and the increase of
Table 2
Operative details, including type of surgery, age at surgery, indications, possible postoper-
ative complications, as well as fecal calprotectin levels before and after surgery.
Type of first bowel resection for CD, n (%)
Small bowel resection 6 (27%)
Ileocecal resection 15 (68%)
Left hemicolectomy 1 (4.5%)
Median age at surgery (years) 15.1 (14.4–17.6)
Indication for surgery, n (%)
Stricture 10 (45%)
Luminal disease 7 (32%)
Gastrointestinal bleeding 2 (9%)
Perforation 1 (4.5%)
Fistula 1 (4.5%)
Not reported 1 (4.5%)
Postoperative complications
Leakage, n (%) 0 (0%)
Infection, n (%) 2 (9%)
Medications at dischargea
AZA (±5-ASA or metronidazole) 8 (40%)
Metronidazole 4 (20%)
5-ASA 3 (15%)
Anti-TNF-α agents (±other medications) 1 (5%)
None 4 (20%)
Median fecal calprotectin (μg/g)
Before surgery 659 (135–1225)⁎
After surgery 103 (53–284)⁎
CD = Crohn's disease, AZA = azathioprine, TNF-α = tumor necrosis α, 5-ASA = 5-
aminosalicylic acid.
a Reported for 20 patients.
⁎ Significant difference between subgroups (p b 0.05).
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doscopic (r= 0.354, p= 0.011 and r= 0.416, p= 0.006) and histolog-
ical recurrence (r= 0.469, p= 0.002 and r= 0.331, p= 0.042), aswell
aswith Rutgeerts score (r=0.295, p=0.036 and r=0.359, p=0.018).2.4. Diagnostic accuracy of follow-up fecal calprotectin
Follow-up FC was measured within 1.5 (0.20–3.6) months of the
follow-up endoscopy andwas significantly higher in the presence of en-
doscopic recurrence compared to i0-i1 (Fig. 1A, Table 3) aswell as in the
presence of histological recurrence vs. quiescent CD (Fig. 2A, Table 3).
Fig. 1B displays the ROC curve for FC for the prediction of endoscopic re-
currence. The optimal cutoff pointwas 139 μg/g, with sensitivity of 0.73,
specificity of 0.64, positive predictive value (PPV) of 0.68, and negative
predictive value (NPV) of 0.70. For the detection of histological recur-
rence, the optimal cutoff point was 101 μg/g, with sensitivity of 0.85,
specificity of 0.63, PPV of 0.79, and NPV of 0.71, respectively (Fig. 2B).Table 3
Fecal calprotectin (FC) levels and postoperative increase of FC according to follow-up endoscop
n (%) n (%) on immunosuppressive medication
Endoscopic recurrence
No (i0-i1) 25 (49%) 15 (60%)⁎
Yes (i2-i4) 26 (51%) 23 (88%)⁎
Endoscopic scoring
i0 8 (16%) 5 (63%)⁎
i1 17 (33%) 10 (59%)⁎
i2 5 (10%) 4 (80%)
i3 5 (10%) 4 (80%)
i4a 16 (31%) 15 (100%)⁎
Histological recurrenceb
No (quiescent CD) 16 (37%) 8 (50%)
Yes (active inflammation) 27 (63%) 22 (81%)
CD = Crohn's disease.
a Medication data at endoscopy missing in one patient.
b Histological reports available for 43 endoscopies.
⁎ Significant difference between subgroups (p b 0.05).2.5. Diagnostic accuracy of the increase of fecal calprotectin
When compared to first postoperative FC, the concentration of FC
increased significantlymore in patients with either endoscopic or histo-
logical recurrence vs. no recurrence (Table 3, p = 0.007 for endoscopic
recurrence and p = 0.044 for histological recurrence). The respective
AUROC value for detection of endoscopic recurrence was 0.74 (95% CI
0.59–0.89) and the optimal cutoff value 79 μg/g, with sensitivity of
0.73, specificity of 0.71, PPV of 0.73, and NPV of 0.71. For detection of
histological recurrence, the AUROC value was 0.70 (95% CI 0.53–0.87)
with an optimal cutoff value of 21 μg/g, sensitivity of 0.74, specificity
of 0.67, PPV of 0.77, and NPV of 0.63, respectively.
Combining two predictors in the same model – the increase of FC
and FC at time of endoscopy – improved the diagnostic accuracy for
the detection of histological recurrence. The AUROC value of the combi-
nationmodel was 0.81 (95% CI 0.67–0.95), with sensitivity and specific-
ity of 0.78 and 0.80 (p=0.001). For detection of endoscopic recurrence,
the combination model resulted in an AUROC value of 0.74 (95% CI
0.58–0.89), with sensitivity and specificity of 0.64 and 0.89 (p =
0.008), respectively.
2.6. Follow-up characteristics
All patients were alive at last follow-up 5.7 (4.2–7.7) years postoper-
atively. Either endoscopic or histological recurrence had occurred in 77%
(n = 17) of patients during follow-up. Fig. 3 illustrates the behavior of
FC before and after surgery aswell as during follow-up. One third of pa-
tients (n = 8) required further operations during follow-up, including
small bowel resections (n = 5 patients), ileocecal resections (n = 4),
colectomy (n = 2), proctectomy or proctocolectomy with an
endostomy (n = 2), and colon resection (n = 1). Postoperatively, aza-
thioprine (AZA) had been used by 52% (n = 11), anti-tumor necrosis
factor (TNF)-α agents by 62% (n = 13), and methotrexate (MTX) by
29% (n = 6). Four patients (19%) had not required other medications
than metronidazole. No risk factors related to recurrence or need for
second surgery were identified; sex, age at diagnosis, age at operation,
disease duration prior to surgery, stricturizing or penetrating disease
behavior, preoperative FC, first postoperative FC, use of thiopurines,
anti-TNF-α agents, orMTXdid not differ betweenpatientswith orwith-
out recurrence or further surgery during follow-up (data not shown).
3. Discussion
This is the first study evaluating the diagnostic accuracy of FC in the
prediction of postoperative recurrence of CD in children. As previouslyy findings.
Fecal calprotectin at endoscopy (μg/g) Increase of fecal calprotectin (μg/g)
111 (31–230)⁎ −1 (−151 to 170)⁎
451 (112–1066)⁎ 320 (42–996)⁎
224 (98–523) −5 (−151 to 212)
103 (29–222)⁎ 3 (−38 to 170)
28 (24–35) 3.5 (−39 to 1057)
189 (148–449) 138 (107–267)
700 (207–1279)⁎ 479 (129–996)
74 (16–185)⁎ −1 (−29 to 128)⁎
230 (112–857)⁎ 318 (17–820)⁎
Fig. 1. Box plots of postoperative fecal calprotectin (FC) (μg/g) levels (A) at time of follow-up endoscopy in pediatric Crohn patients with (n= 26) or without (n= 25) endoscopic recur-
rence as well as ROC curve for FC for detection of endoscopic recurrence (B). The length of the box represents the IQR within which 50% of the values are located. The line through the
middle of each box represents the median. Error bars show minimum and maximum values. The round dots represent values larger than the upper quartile plus 1.5 times the IQR. The
area under the ROC curve was 0.71 (95% CI 0.56-0.85).
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first weeks after surgery and increased during follow-up in patients
with recurrent disease. FCwas a relatively accurate predictor of both en-
doscopic and histological disease recurrence with AUROC values of 0.71
and 0.78. Even though this is a retrospective study based on a small
sample, our results strongly suggest postoperative FC behaves in chil-
dren and adolescents similarly as previously demonstrated among
adult CD patients [8,25].
Fasting, bowel preparation, and requirement of anesthesia make en-
doscopies particularly demanding for children. As endoscopies are also
invasive, expensive, and time-consuming with a risk of complications,
there is a need for noninvasive screeningmethods for detecting relapseFig. 2. Box plots of postoperative fecal calprotectin (FC) (μg/g) levels (A) at time of follow-up e
currence as well as ROC curve for FC for detection of histological recurrence (B). The length of
the middle of each box represents the median. Error bars show minimum and maximum valu
The area under the ROC curve was 0.78 (95% CI 0.64–0.92). CD= Crohn's disease.and postoperative recurrence of CD. Clinical activity indices and serum
inflammatorymarkers correlate poorlywith endoscopic disease activity
[9,17,18,21]. Fecal calprotectin, which is excreted by migrating neutro-
phils to the lumen of the inflamed bowel, has been demonstrated a use-
ful surrogate marker for disease activity in both children and adults
[18,21,22,31,32]. However, FC is not specific to inflammatory bowel dis-
ease and may increase in the presence of other gastrointestinal disor-
ders, such as infectious colitis and polyposis [33,34]. In addition, bowel
leaks and abscessesmay raise the level of FC for severalweeks and com-
plicate its interpretation in the postoperative setting [27].
Despite resolution of active mucosal inflammation during medical
therapy for CD, FC levels may remain elevated reflecting persistentndoscopy in pediatric Crohn patients with (n = 27) or without (n = 16) histological re-
the box represents the IQR within which 50% of the values are located. The line through
es. The round dots represent values larger than the upper quartile plus 1.5 times the IQR.
Fig. 3. Preoperative, postoperative, and follow-up fecal calprotectin (FC) measurements presented for all cases with preoperative FC measurement available (n = 17).
1471M. Hukkinen et al. / Journal of Pediatric Surgery 51 (2016) 1467–1472microscopic inflammation of the bowel wall [17,18,21,22,31,32]. Sug-
gested cutoff values for detection of relapse vary between 150 and
275 μg/g, usually with moderate sensitivity but good specificity
[17,18,21,32]. Instead, after successful surgery, FC levels should normal-
ize, and consequently the cutoff values for detection of postoperative re-
currence are lower [8,25,27,35]. Recent studies among adults report
sensitivity and specificity values of 0.82–0.89 and 0.58–0.61 for FC for
the prediction of endoscopic recurrence after surgery and suggest FC
levels above 100 μg/g as an indication for endoscopy [8,25,36]. Accord-
ingly, we found FC levels in children to fall close to 100 μg/g after surgery,
and cutoffs of 139 μg/g and 101 μg/g predicted the presence of endoscop-
ic and histological recurrence with good sensitivity. On the other hand,
an increase of 20–80 μg/g compared to postoperative FC level was sug-
gestive of disease recurrence. Compared to nonoperated patients, both
children and adults, FC appears to be a more delicate marker of mucosal
inflammation in the postoperative setting when it detects the early in-
flammatory changes developing in a previously unaffected intestine.
The few studies that have evaluated FC in relation to histology of CD
report a high correlationwith biopsy-proven disease activity [17,32,37].
One strength of our study is that both endoscopic and histological dis-
ease activities were evaluated. Consistent with previous findings, we
found FC a sensitive marker of histological inflammation. Although the
best cutoff of 101 μg/g for detection of histological inflammation was
no different from median postoperative FC and therefore inconvenient
for clinical use, taking into account also the postoperative increase of
FC improved its diagnostic accuracy, resulting in an AUROC value of
0.81. In clinical practice, following the postoperative trend of FC instead
of single measurements would probably be useful.
Lower levels of FC were observed in the presence of histological re-
currence compared to endoscopic recurrence. Histological derangement
with an early-stage inflammation precedes the development of ulcers
[11,38], and likely increases FC concentration before any disease activity
can be observed in endoscopy. The rapid development of inflammation
at the site of anastomosis has been suggested to result from the back-
wash of intestinal contents in the case of ileocecal resection [11]. Indeed,
despite endoscopic grading of i0-i1, biopsies suggested active inflam-
mation in seven of our patients with previous ileocecal resection and
the inflammatory changes were located in the neoterminal ileum or at
the anastomosis in five of them. However, biopsies may also give false
negative results as they are not necessarily taken from areas of inflam-
mation. Poor visibility and bowel preparation as well as the presence
of strictures or transmural inflammation under a healthy-lookingmuco-
sa may in turn result in false endoscopic grading [39]. As both scaling
systems are subject to intraobserver and interobserver variability, biop-
sy specimens should be routinely taken in endoscopies performed for
CD patients to improve the accuracy of the examination and to facilitate
later decision-making [17,39].A recent multicenter randomized trial among adult CD patients rec-
ommended postoperative endoscopic monitoring at 6-month intervals
[9]. FC measurement could reduce the need for postoperative
ileocolonoscopies by recognizing patients with probable disease recur-
rence who require medication intensification. By using the best cutoff
of 139 μg/g for endoscopic recurrence, 19 out of 26 patientswith disease
recurrence were correctly recognized, whereas a lower cutoff of 112 μg/
g would give sensitivity and specificity values of 0.77 and 0.52. Postop-
erative FC values clearly over 100 μg/g should raise a suspicion of dis-
ease recurrence [8,25,36]. In case of indeterminate results, FC is easy
to control at short time intervals. Further, as FC is supposed to decrease
near 100 μg/g after successful surgery, the postoperative increase of FC
may serve as another useful method when deciding whether stepping
up medication would be necessary.
The present study is limited by its small sample size, retrospective
nature, and the lack of routine postoperative FC and endoscopic moni-
toring, which resulted in relatively long time gaps between surgery
and follow-up endoscopies. However, FC measurements were obtained
within median 1.5 months of follow-up endoscopy and therefore likely
reflected the endoscopic disease activity reliably. Despite some limita-
tions, this is the first report on postoperative FC measurement among
pediatric patients and our results suggest postoperative FC can be
interpreted in children similarly than earlier demonstrated among
adult patients. Monitoring FC is currently part of our routine follow-up
in children having undergone surgery for CD. By using recurrent FC
measurements, postoperative endoscopies could be spared to children
who have signs of complicated CD or who fail to respond to therapy.
In conclusion, postoperative FC levels predicted both endoscopic and
histological recurrence of CD relatively accurately in a small sample of
patients having undergone bowel resection during childhood. FC levels
decreased near normal after surgery and increased significantly in pa-
tients with recurrent disease in a similarmanner as previously reported
in adults. FC is a promising surrogate marker of postoperative CD recur-
rence also in children and adolescents, and its use may reduce the need
for endoscopic monitoring after surgery.
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